In this issue of Blood, Rak et al identify cytohesin 1 (CYTH1) as an important intracellular mediator of human hematopoietic stem cell (HSC) adhesion that plays a role in HSC homing and lodging in the bone marrow and subsequent engraftment.
1 This finding contributes to our understanding of the mechanisms involved in regulating HSC-niche interaction, which we know is critical in regulating HSC function. 2 M uch effort over the years has revealed many cell surface players responsible for the ability of HSCs to interact with the bone marrow microenvironment. 3 Integrins in particular have emerged as critical players in the adhesion of HSCs to the extracellular matrix, with integrin b1 (ITGb1) knockout leading to severe homing defects. 4 because it introduces high shear stress, and decided to take advantage of gravity, which naturally acts on all cells in any organisms, to identify genes that precisely regulate the adhesion properties of human HSPCs. Using the analogy of a car, which moves thanks to the interaction of the wheels with the road, while the steering wheel determines the direction of movement, this screening allowed the identification of wheel components, and the ensuing study focused on a factor akin to the wheels' axis. All top hits identified, including CD90, ITGa5, MMRN1, NEDD9, PPFIA1, and ROBO1 had previously been described as components of cellular molecular motors. Importantly, known genes involved in HSPC localization but acting through different mechanisms (eg, chemoattraction in the case of CXCR4), were not highlighted by this screening. In this study, CYTH1 is knocked down via shRNA in human HSPCs, resulting in their reduced adhesion to both retronectin (mediated by ITGb1) and ICAM1 (mediated by ITGb2) and reduced integrin activation in in vitro assays. When human HSCs deficient in CYTH1 are challenged to engraft in immunodeficient NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice, they show reduced ability to home to the bone marrow, lodge within the parenchyma, and drive efficient long-term engraftment. A member of another family of guanine exchange factors and linked to the regulation of Rho GTPases, Vav1, was previously shown to contribute to murine HSPC localization in the bone marrow and subsequent engraftment, 9 with Vav1 knockout HSPCs showing a phenotype similar to that of the human cytohesin-deficient HSPCs in the Rak et al study. Rak et al take advantage of more recently developed time-lapse intravital microscopy of engrafting HSPCs 10 to unravel the mechanism behind the observed aberrant HSPC localization. Fluorescently labeled CYTH1-deficient HSPCs were injected in NSG recipient mice, and intravital microscopy revealed that most cells found 4 days later were unable to settle in the marrow parenchyma in the same way as control cells. The homing and lodgment defects observed are not as severe as the engraftment reduction, and the low levels of engrafted hematopoiesis show balanced differentiation. The cell cycle profile of cytohesin-deficient cells is unaffected, suggesting that a fraction of the observed HSPCs are able to engraft. This raises the questions of whether the nonengrafting HSPCs prematurely differentiate or die, whether the few engrafting HSPCs are those showing localization and migration more similar to control cells, and what is the differentiation and functional state of both control and knockdown cells observed. Even though CYTH1 is efficiently knocked down in all HSPCs assessed through functional studies, some engraftment is obtained. This fact points to the complexity and robustness of the phenomena studied, whereby deficiency in one component does not completely obliterate a cellular function-in this case adhesion and migration-in an entire cell population, and other mechanisms can still rescue CYTH1 deficiency. Future studies will indicate whether this is achieved through highly defined and uniform compensatory mechanisms or is the result of stochastic and variable activation of other components of the HSPCs' molecular motors.
Conflict-of-interest disclosure: The author declares no competing financial interests. n 
Eculizumab: another breakthrough -----------------------------------------------------------------------------------------------------Robert A. Brodsky JOHNS HOPKINS UNIVERSITY
In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement. 1 P NH is a clonal hematopoietic stem cell disease associated with a complementdependent hemolytic anemia.
2 The disease manifests after the expansion of a multipotent hematopoietic stem cell that acquires a mutation of the PIGA gene. The PIGA gene product is required for the biosynthesis of glycophosphatidylinositol anchors, a glycolipid moiety that attaches dozens of proteins to the plasma membrane of cells. Thus, all blood cells derived from the PIGA mutant stem cell, including mature red blood cells, are missing glycophosphatidylinositol-anchor proteins. Two of these proteins, CD55 and CD59, are complement regulatory proteins. CD55 inhibits C3 convertases, and CD59 blocks formation of the membrane attack complex (MAC) by inhibiting incorporation of C9 into the MAC. Harder et al performed a series of elegant ex vivo experiments to model breakthrough hemolysis of PNH red cells in the setting of C5 inhibition and to improve our understanding of the mechanism of action of eculizumab. The authors demonstrate that residual lytic activity of the terminal pathway of complement depends on the strength of the complement activator and the resulting surface density of C3b, which amplifies the alternative pathway through its potent amplification loop (see figure) . They also show that at high densities of C3b on red cells, C5 inhibitors such as eculizumab and the tick-derived C5 inhibitor OmcI (Coversin) 5 reduce but do not abolish terminal complement activity. Thus, C5 inhibitors stabilize the unprimed C5 conformation, making it much less susceptible to cleavage by convertases. C5 is more susceptible to cleavage under conditions of more intense priming due to excess C3b on the red cells, even in the presence of a C5 inhibitor. Interestingly, a combination of eculizumab and Coversin, which bind to different epitopes of C5, has additive effects and together can abolish residual lytic activity even in the presence of strong activation. Similarly, combining eculizumab with drugs or conditions that inhibit the amplification loop of
